The trial which is sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), expects to recruit around 60 HIV infected patients.
The HIV vaccine trial is expected to evaluate the safety and immunogenicity of increasing doses of the rVSVIN HIV-1 gag vaccine administered by intramuscular injection.
Profectus chief scientific officer John Eldridge said the company is very excited about the future of the rVSV vector platform, because of its potential to induce long-lived immune responses in mucosal tissues, the portals of HIV-1 entry.
"This clinical study should provide a pathway for improved immunogenicity and efficacy in combination with our proprietary plasmid DNA vectors," Eldridge said.